30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Monopar Therapeutics Inc (MNPR)

Track

The most recent insider trading activity occurred on December 26, 2025, with a BUY transaction by the Chief Financial Officer. Prior to this, significant SELL transactions were noted in late 2025 and mid-2025 by various executives and entities, including the CEO and a 10% stockholder. Earlier BUY transactions by other officers were recorded in late 2024 and mid-2024.
Stock chart
Ticker: MNPR Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Vu Quan Anh
Chief Financial Officer
1 purchase — total 104,925 USD
Buy 26 Dec 2025
Value US$4,191,643.21 | Price 91.02 | Shares 94,669
Proposed sale 18 Dec 2025
Value US$1,957,153.50 | Price 459.54 | Shares 31,184
Sale 18 Dec 2025
Value US$31,389.49 | Price 68.09 | Shares 461
Sale 18 Dec 2025
Value US$312,499.60 | Price 67.06 | Shares 4,660
Sale 24 Sep 2025
Value US$34,999,956.64 | Price 63.61 | Shares 550,229
Sale 14 Jul 2025
Value US$672,020.16 | Price 40.00 | Shares 16,800
Proposed sale 14 Jul 2025
Value US$672,000.00 | Price 40.00 | Shares 16,800
Sale 14 Jul 2025
Value US$672,020.16 | Price 40.00 | Shares 16,800
Proposed sale 14 Jul 2025
Value US$672,000.00 | Price 40.00 | Shares 16,800
Sale 14 Jul 2025
Value US$356,170.68 | Price 40.00 | Shares 8,904
Proposed sale 14 Jul 2025
Value US$356,160.00 | Price 40.00 | Shares 8,904
Sale 2 Apr 2025
Value US$1,166,690.00 | Price 35.00 | Shares 33,334
Proposed sale 2 Apr 2025
Value US$1,166,806.00 | Price 35.00 | Shares 33,334
Buy 28 Oct 2024
Value US$25,187.50 | Price 16.25 | Shares 1,550
Buy 20 Jun 2024
Value US$15,253.85 | Price 0.74 | Shares 20,508
Buy 18 Jun 2024
Value US$10,320.00 | Price 0.86 | Shares 12,000
Buy 17 Jun 2024
Value US$10,798.80 | Price 0.90 | Shares 12,000
Buy 14 Jun 2024
Value US$11,175.60 | Price 0.93 | Shares 12,000
Buy 13 Jun 2024
Value US$10,920.00 | Price 0.91 | Shares 12,000
Buy 4 Jun 2024
Value US$9,360.00 | Price 0.78 | Shares 12,000
Buy 3 Jun 2024
Value US$9,120.00 | Price 0.76 | Shares 12,000
Buy 31 May 2024
Value US$7,731.60 | Price 0.64 | Shares 12,000
Buy 30 May 2024
Value US$7,676.40 | Price 0.64 | Shares 12,000
Buy 29 May 2024
Value US$7,642.80 | Price 0.64 | Shares 12,000
Buy 15 Nov 2022
Value US$31,500.00 | Price 3.15 | Shares 10,000
Buy 14 Nov 2022
Value US$18,159.00 | Price 3.00 | Shares 6,053
Planned sale 11 Feb 2021
Value US$201,600.10 | Price 16.90 | Shares 11,929
Planned sale 11 Feb 2021
Value US$269,352.96 | Price 16.44 | Shares 16,384
Planned sale 11 Feb 2021
Value US$453,539.52 | Price 15.12 | Shares 29,996
Planned sale 11 Feb 2021
Value US$341,316.16 | Price 14.09 | Shares 24,224
Planned sale 11 Feb 2021
Value US$564,811.10 | Price 13.30 | Shares 42,467
Buy 18 Dec 2019
Value US$2,600.00 | Price 8.00 | Shares 325
Buy 18 Dec 2019
Value US$1,000,000.00 | Price 8.00 | Shares 125,000
Buy 18 Dec 2019
Value US$3,750,000.00 | Price 8.00 | Shares 468,750
Buy 18 Dec 2019
Value US$2,510.00 | Price 8.00 | Shares 314
Buy 18 Dec 2019
Value US$1,250,000.00 | Price 8.00 | Shares 156,250
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-29 2025-12-26 B Purchase
1.6
Vu Quan Anh

Chief Financial Officer

Officer
94,669 -3.2%
91.02
US$4,191,643 		94,669 -3.2% 91.02 US$4,191,643
2025-12-19 2025-12-18 PrS Proposed sale
2.3
Arthur Klausner

Board Member
31,184
459.54
US$1,957,153 		31,184 459.54 US$1,957,153
2025-12-19 2025-12-18 S Sale
2.3
KLAUSNER ARTHUR J
Non-Executive Director
9,775 -24.1%
313.10
US$4,621,833 		9,775 -24.1% 313.10 US$4,621,833
2025-12-19 2025-12-18 S Sale
2.3
KLAUSNER ARTHUR J
Non-Executive Director
4,660 -33.6%
67.06
US$312,500 		4,660 -33.6% 67.06 US$312,500
2025-09-26 2025-09-24 S Sale
1.3
Tactic Pharma LLC

Chief Executive Officer

Executive Director Large shareholder
550,229 -66.9%
63.61
US$34,999,957 		550,229 -66.9% 63.61 US$34,999,957
2025-07-16 2025-07-14 S Sale
1.4
STARR CHRISTOPHER M
Non-Executive Director
16,800 -76.5%
40.00
US$672,020 		16,800 -76.5% 40.00 US$672,020
2025-07-16 2025-07-14 S Sale
1.4
Robinson Chandler

Chief Executive Officer

Executive Director
16,800 -18.6%
40.00
US$672,020 		16,800 -18.6% 40.00 US$672,020
2025-07-16 2025-07-14 S Sale
1.4
Tsuchimoto Kim R
Non-Executive Director
8,904 -43.7%
40.00
US$356,171 		8,904 -43.7% 40.00 US$356,171
2025-07-14 2025-07-14 PrS Proposed sale
1.4
STARR CHRISTOPHER M

Director

Non-Executive Director
16,800
40.00
US$672,000 		16,800 40.00 US$672,000
2025-07-14 2025-07-14 PrS Proposed sale
1.4
Tsuchimoto Kim R

Director

Non-Executive Director
8,904
40.00
US$356,160 		8,904 40.00 US$356,160
2025-07-14 2025-07-14 PrS Proposed sale
1.4
Robinson Chandler

Officer; Director

Executive Director
16,800
40.00
US$672,000 		16,800 40.00 US$672,000
2025-04-04 2025-04-02 S Sale
1.3
Tactic Pharma LLC

Chief Executive Officer

Executive Director Large shareholder
33,334 -3.9%
35.00
US$1,166,690 		33,334 -3.9% 35.00 US$1,166,690
2025-04-02 2025-04-02 PrS Proposed sale
1.3
Tactic Pharma LLC

10% Stockholder

Large shareholder
33,334
35.00
US$1,166,806 		33,334 35.00 US$1,166,806
2024-10-30 2024-10-28 B Purchase
2.4
Radhakrishnan Karthik

Chief Financial Officer

Officer
1,550 +inf%
16.25
US$25,188 		1,550 +inf% 16.25 US$25,188
2024-06-21 2024-06-20 B Purchase
2.4
Cittadine Andrew

Chief Operating Officer

Officer
20,508 +12.4%
0.74
US$15,254 		20,508 +12.4% 0.74 US$15,254
2024-06-21 2024-06-18 B Purchase
2.4
Cittadine Andrew

Chief Operating Officer

Officer
12,000 +7.8%
0.86
US$10,320 		12,000 +7.8% 0.86 US$10,320
2024-06-17 2024-06-17 B Purchase
2.4
Cittadine Andrew

Chief Operating Officer

Officer
12,000 +8.5%
0.90
US$10,799 		12,000 +8.5% 0.90 US$10,799
2024-06-17 2024-06-14 B Purchase
2.4
Cittadine Andrew

Chief Operating Officer

Officer
12,000 +9.3%
0.93
US$11,176 		12,000 +9.3% 0.93 US$11,176
2024-06-17 2024-06-13 B Purchase
2.4
Cittadine Andrew

Chief Operating Officer

Officer
12,000 +10.2%
0.91
US$10,920 		12,000 +10.2% 0.91 US$10,920
2024-06-05 2024-06-04 B Purchase
2.4
Cittadine Andrew

Chief Operating Officer

Officer
12,000 +11.4%
0.78
US$9,360 		12,000 +11.4% 0.78 US$9,360
2024-06-05 2024-06-03 B Purchase
2.4
Cittadine Andrew

Chief Operating Officer

Officer
12,000 +12.8%
0.76
US$9,120 		12,000 +12.8% 0.76 US$9,120
2024-05-31 2024-05-31 B Purchase
2.4
Cittadine Andrew

Chief Operating Officer

Officer
12,000 +14.7%
0.64
US$7,732 		12,000 +14.7% 0.64 US$7,732
2024-05-31 2024-05-30 B Purchase
2.4
Cittadine Andrew

Chief Operating Officer

Officer
12,000 +17.2%
0.64
US$7,676 		12,000 +17.2% 0.64 US$7,676
2024-05-31 2024-05-29 B Purchase
2.4
Cittadine Andrew

Chief Operating Officer

Officer
12,000 +20.8%
0.64
US$7,643 		12,000 +20.8% 0.64 US$7,643
2022-11-16 2022-11-15 B Purchase
2.4
Cittadine Andrew

Chief Operating Officer

Officer
10,000 +70.2%
3.15
US$31,500 		10,000 +70.2% 3.15 US$31,500
2022-11-16 2022-11-14 B Purchase
2.4
Cittadine Andrew

Chief Operating Officer

Officer
6,053 +74.0%
3.00
US$18,159 		6,053 +74.0% 3.00 US$18,159
2021-02-16 2021-02-11 PlS Planned sale
1.3
Tactic Pharma LLC

Chief Scientific Officer

Large shareholder
11,929 -6.7%
16.90
US$201,600 		11,929 -6.7% 16.90 US$201,600
2021-02-16 2021-02-11 PlS Planned sale
1.3
Tactic Pharma LLC

Chief Scientific Officer

Large shareholder
16,384 -8.4%
16.44
US$269,353 		16,384 -8.4% 16.44 US$269,353
2021-02-16 2021-02-11 PlS Planned sale
1.3
Tactic Pharma LLC

Chief Scientific Officer

Large shareholder
29,996 -13.3%
15.12
US$453,540 		29,996 -13.3% 15.12 US$453,540
2021-02-16 2021-02-11 PlS Planned sale
1.3
Tactic Pharma LLC

Chief Scientific Officer

Large shareholder
24,224 -9.7%
14.09
US$341,316 		24,224 -9.7% 14.09 US$341,316
2021-02-16 2021-02-11 PlS Planned sale
1.3
Tactic Pharma LLC

Chief Scientific Officer

Large shareholder
42,467 -14.6%
13.30
US$564,811 		42,467 -14.6% 13.30 US$564,811
2019-12-20 2019-12-18 B Purchase Tsuchimoto Kim R

Chief Financial Officer
325 +inf%
8.00
US$2,600 		325 +inf% 8.00 US$2,600
2019-12-20 2019-12-18 B Purchase Tactic Pharma LLC

Chief Scientific Officer
125,000 +75.0%
8.00
US$1,000,000 		125,000 +75.0% 8.00 US$1,000,000
2019-12-20 2019-12-18 B Purchase Hendricks Diane
468,750 +inf%
8.00
US$3,750,000 		468,750 +inf% 8.00 US$3,750,000
2019-12-20 2019-12-18 B Purchase Leo Karl
314 +inf%
8.00
US$2,510 		314 +inf% 8.00 US$2,510
2019-12-20 2019-12-18 B Purchase Leo Karl
156,250 +inf%
8.00
US$1,250,000 		156,250 +inf% 8.00 US$1,250,000
Explore more

More insider trading research around Monopar Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America